

AMENDMENT

U.S. Appln. No. 09/576,951

B1 cont  
42 position, a rapamycin having a linking group at the 31 position, and a rapamycin having a linking group at both the 42 position and the 31 position, wherein said molecule is conjugated to an immunogenic carrier material via said linking group.

B2  
Claim 37. (Amended) The monoclonal antibody of Claim 33, wherein said immunogenic carrier material is a protein selected from the group consisting of keyhole limpet hemocyanin and ovalbumin.

Please add the following new claims:

inf 0.5-1  
-- Claim 41. A monoclonal antibody which specifically binds to an antigen which is specifically bound by the monoclonal antibody secreted by hybridoma RAP-42-OVAF<sub>2</sub>#1hc, wherein said hybridoma has been deposited and accorded ATCC Accession No. 11568.

Claim 42. A monoclonal antibody according to any one of Claims 33, 34, 35, 36, 37, or 38, obtained by:

- (a) administering said immunogen to an appropriate animal species to effect immunogenic challenge and recovery of antibody producing-cells sensitized to said immunogen;
- (b) immortalizing said antibody-producing cells; and
- (c) recovering said monoclonal antibody from a selected immortalized cell line thus established.

Sub 3  
C1  
Claim 43. A hybridoma capable of producing a monoclonal antibody as defined in any one of Claims 33, 34, 35, 36, 37, 38 or 41.